product name Atomoxetine HCl
Description: Atomoxetine (also known as LY 139603 HCl) is a selective norepinephrine (NE) transporter inhibitor with Ki of 5 nM, with 15- and 290-fold lower affinity for human 5-HT and DA transporters. In microdialysis studies in rat, atomoxetine increases extracellular levels of norepinephrine transporter in prefrontal cortex 3-fold without altering 5-HTEX levels. Atomoxetine also increases DAEX concentrations in PFC 3-fold without altering DAEX in striatum or nucleus accumbens.
References: Neuropsychopharmacology. 2002 Nov;27(5):699-711; J Pharmacol Exp Ther. 1985 Jan;232(1):139-43.
291.82
Formula
C17H21NO.HCl
CAS No.
82248-59-7
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 58 mg/mL (198.8 mM)
Water: 2 mg/mL (6.8 mM)
Ethanol: 37 mg/mL (126.8 mM)
Solubility (In vivo)
Synonyms
LY 139603 HCl
other peoduct :
| In Vitro |
In vitro activity: Atomoxetine is a selective norepinephrine reuptake inhibitor with Ki of 5 nM, compared with 77 and 1451 nM for binding to serotonin and dopamine transporters. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | In microdialysis studies, atomoxetine increases extracellular (EX) levels of NE in prefrontal cortex (PFC) 3-fold, but does not alter 5-HTEX levels. Atomoxetine also increases DAEX concentrations in PFC 3-fold, but does not alter DAEX in striatum or nucleus accumbens. Atomoxetine increases Fos by 3.7-fold in PFC, but not in the striatum or nucleus accumbens. Atomoxetine selectively inhibits the presynaptic uptake of norepinephrine in adrenergic neurons in animals, and has activity in animal models of depression. |
| Animal model | |
| Formulation & Dosage | |
| References | Neuropsychopharmacology. 2002 Nov;27(5):699-711; J Pharmacol Exp Ther. 1985 Jan;232(1):139-43. |
